BSLN — Basilea Pharmaceutica AG Allschwil Income Statement
0.000.00%
Last trade - 00:00
- CH₣484.66m
- CH₣535.63m
- CH₣157.63m
- 42
- 18
- 46
- 25
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 134 | 128 | 148 | 148 | 158 |
Cost of Revenue | |||||
Gross Profit | 116 | 104 | 124 | 123 | 131 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 152 | 136 | 147 | 129 | 138 |
Operating Profit | -17.2 | -8.54 | 0.69 | 18.5 | 19.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22.4 | -14.7 | -6.79 | 12.1 | 10.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -22.4 | -14.7 | -6.83 | 12.1 | 10.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -22.4 | -14.7 | -6.83 | 12.1 | 10.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -22.4 | -14.7 | -6.83 | 12.1 | 10.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.08 | -2.36 | -0.558 | 1.03 | 0.872 |
Dividends per Share |